CHINARES PHARMA(03320): China Resources Boya Bio-pharmaceutical Group(300294.SZ) expects the net profit attributable to the parent company to increase by about 380-480 million yuan in 2024 compared to the previous year.

CHINARES PHARMA (03320) announced that on January 22, 2025, its subsidiary China Resources Boya Bio-pharmaceutical Group (300294.SZ) released its performance forecast for the year ending December 31, 2024. According to this, the net profit attributable to shareholders of China Resources Boya Bio-pharmaceutical Group for the year ended December 31, 2024 is expected to be approximately RMB 3.8 billion to 4.8 billion (compared to RMB 2.37 billion in the same period last year), and the net profit attributable to shareholders of China Resources Boya Bio-pharmaceutical Group after deducting non-recurring gains and losses is expected to be approximately RMB 2.84 billion to 3.84 billion (compared to RMB 1.43 billion in the same period last year), with an estimated basic earnings per share of approximately RMB 0.75 to RMB 0.95 (compared to RMB 0.47 in the same period last year). The main reasons for the changes in China Resources Boya Bio-pharmaceutical Group's performance in 2024 compared to the same period last year are the growth in blood product revenue in 2024, the lower base caused by impairment losses on goodwill and other assets in 2023, and an increase in blood collection volume in 16 operating plasma stations (excluding 4 in Chongqing Green Cross (China) Biological Products Co., Ltd.) by 11.71% year-on-year to 522.04 tons. Additionally, non-recurring gains and losses are expected to have an impact of about RMB 96.26 million on China Resources Boya Bio-pharmaceutical Group's net profit during the reporting period from January 1 to December 31, 2024.